Imidlertid er virkningen af tidlig behandling med AVONEX uvis selv i denne høj- risiko undergruppe, da studiet hovedsageligt var designet til at bestemme tidspunktet for et nyt anfald frem for langtidsudviklingen af sygdommen.
However, the impact of early treatment with AVONEX is unknown even in this high-risk subgroup as the study was mainly designed to assess the time to the second event rather than the long term evolution of the disease.